To further examine whether the observed synergistic inhibitory effect of HK2 inhibitor and doxorubicin on tumor growth in vivo was due to direct inhibition on tumor cells or through modulating TPC function, we treated LLC cells with either placebo, 3-BP, doxorubicin or 3-BP, and doxorubicin combination in vitro, indicating that co-administration of 3-BP and doxorubicin had no synergistic inhibitory effect on LLC tumor cell growth in vitro (Supplementary fig. 8t). The gene discussed is HK2; the disease is neoplasm.